MIRM
Mirum Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 105 | +1 | 35.65M | $4.17B | +8 | −7 |
| Q1 2026 | 107 | +6 | 39.52M | $3.63B | +12 | −7 |
| Q4 2025 | 102 | +1 | 36.05M | $2.83B | +2 | n/a |
| Q3 2025 | 20 | 0 | 17.64M | $1.29B | n/a | n/a |
| Q2 2025 | 17 | +1 | 13.61M | $692.65M | +2 | −1 |
| Q1 2025 | 13 | +1 | 7.45M | $335.67M | +2 | −1 |
| Q4 2024 | 12 | 0 | 6.63M | $274.04M | +1 | −1 |
| Q3 2024 | 11 | +2 | 4.84M | $188.84M | +2 | n/a |
| Q2 2024 | 9 | n/a | 4.39M | $149.94M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 1.59M | n/a | $54.21M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 2 | T. Rowe Price ✦ | 1.20M | n/a | $41.00M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 907.18K | n/a | $31.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 265.44K | n/a | $9.08M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 163.54K | n/a | $5.59M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 160.00K | n/a | $5.47M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 75.42K | n/a | $2.58M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 20.52K | n/a | $701,580 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 8.29K | n/a | $283,572 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 308 holders, 67.83M shares, $6.01B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 9.94K sh · $978,093
Officer · 658 sh · $65,800
Officer · 40.00K sh · $4.00M
Officer · 6.00K sh · $599,510
Officer, Director · 2.30K sh · $230,322
Officer, Director · 6.02K sh · $597,187
Officer, Director · 11.68K sh · $1.15M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology